Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 24, 2008

Luminex and BD Ally to Develop Tests for Cancer Prediction

  • Luminex and BD are joining forces to develop molecular diagnostics for certain cancers. BD Diagnostics-TriPath will develop, market, and sell these tests using Luminex’ multiplexing xMAP® Technology platform.

    BD develops technologies for cervical cancer screening as well as diagnostic products for the detection of cancer. The aim is to expand its offerings to include tests for solid tumor cancers using Luminex' platform.

    The xMAP Technology is a multiplexing platform that allows scientists to conduct multiple, simultaneous tests on one patient sample. “We believe providing biomarker testing in a multiplex format would allow detection of cancer at an earlier stage,” says Wayne Brinster, vp and GM of BD Diagnostics-TriPath.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »